White Paper: Considerations for the Clinical Development of Cell & Gene Therapies (Part 1: Cell Therapies)
The regenerative medicine category is predicted to generate $39.33 billion in revenue by 2023, with the fastest growth expected in cell therapy.
Article: Mind the Skills Gap
“There’s a little over 1,200 clinical trials worldwide, and about half of those are in the US. Over 100 of those are in phase III, so we’re getting really close to getting more approved.”
ISPE Guide: ATMPs – Autologous Cell Therapy
Article: Mind the Cell & Gene Gap
A 2018 study by Deloitte suggested that more than 2.4 million manufacturing jobs in the US would remain unfilled in 2028 because of the widening – and often generational – skills gap.
On-Demand Webinar: CQV Strategies that Increase Speed-to-Market for Gene Therapy
To successfully increase speed-to-market for gene therapies, having a defined CQV (Commissioning, Qualification, and Validation) strategy is critical to project success. In this webinar co-sponsored by Precision ADVANCE and Project Farma, our panel of industry experts discuss tips for delivering efficient, reliable, GMP-compliant facilities and processes specific to gene therapy.